National Health Act 1953 - Amendment determination under section 84AF - responsible persons (No. PB 36 of 2010)

Administered by Department of Health, Disability and Ageing

Legislation au F2010L00938 Not in force Legislative Instrument

Legislation content

 EXPLANATORY STATEMENT

INSTRUMENT NUMBER PB 36 OF 2010

NATIONAL HEALTH ACT 1953

AMENDMENT DETERMINATION UNDER SECTION 84AF

 

Summary

This legislative instrument in giving effect to recommendations of the Pharmaceutical Benefits Advisory Committee (PBAC) amends the determination under section 84AF made by legislative instrument number PB 16 of 2010 which came into effect on 1 April 2010.  The amendments provide for additions and changes to the responsible persons for the brands of pharmaceutical items.  These persons are bodies corporate and are identified by their company name and Australian Business Number (ABN).  The amendments are set out in the items of Schedule 1 to the instrument.

Purpose and operation

Part VII of the National Health Act 1953 (the Act) is the legislative basis of the Pharmaceutical Benefits Scheme (PBS) by which the Commonwealth provides reliable, timely, and affordable access to a wide range of medicines for all Australians.

Subsection 85(1) provides that benefits are to be provided by the Commonwealth in accordance with Part VII in respect of pharmaceutical benefits.

Drugs and medicinal preparations to which Part VII applies are declared by the Minister by legislative instrument to be so under subsection 85(2). These are listed drugs as defined in subsection 84(1).  Part VII also applies to certain extemporaneously-prepared medicinal preparations as a result of declarations under paragraph 85(2)(b).

The Minister by legislative instrument can determine the form or forms of a listed drug by reference to strength, type of unit, size of unit or otherwise (subsection 85(3)); the manner of administration of the form of the listed drug so determined (subsection 85(5)); and a brand of the pharmaceutical item (defined in subsection 84(1)) that has the listed drug in that form with that manner of administration (subsection 85(6)).  These determinations govern (except for certain extemporaneously-prepared pharmaceutical benefits) what constitutes the pharmaceutical benefit (defined in subsection 84(1)) under Part VII of the Act.

Section 84AF empowers the Minister to determine that a person is the responsible person for a brand of a pharmaceutical item.  The Minister can do this if the person has notified the Minister that the person is or will be the supplier of the brand of the pharmaceutical item to wholesalers or, if not, to approved pharmacists directly.  The brand must be a listed brand (defined in subsection 84(1) as a brand in relation to which a determination under subsection 85(6) is in force), and there can be no determination in force that any other person is the responsible person for the brand of the pharmaceutical item or of any other pharmaceutical item.

A responsible person for a brand of pharmaceutical item has various responsibilities or functions under the Act.  These include those in relation to entering into price agreements under section 85AD, compliance with price disclosure requirements under Division 3B, and the requirement to supply certain brands of pharmaceutical item for a specified period under Division 3C.

This instrument determines the responsible persons for the brands of pharmaceutical items set out in Schedule 1 to the instrument.  These persons are bodies corporate and are identified in Schedule 1 by their company name and Australian Business Number (ABN).  The names of the responsible persons were notified before the commencement of section 84AF as permitted by subsection 84AF(2). 

A provision-by-provision description of the instrument is contained in the Attachment.

This instrument, expressed to commence on 1 May 2010, was made on 1 April 2010.

Consultations

This instrument affects pharmaceutical companies with medicines listed on the PBS. In relation to the introduction of the responsible person measure, pharmaceutical companies have been consulted during both the policy development and implementation phases.  This has occurred through meetings with both peak body organisations and individual companies.  Information on this measure has been disseminated through peak industry bodies and during regular meetings with a Stakeholder Reference Group. Particular information on the Responsible Person provisions has been provided by letter to those companies to whom the provisions will apply. Under section 84AF the Minister may only determine a person to be the responsible person for a brand of a pharmaceutical item if the person has notified the Minister that the person is or will be the supplier of the brand of the pharmaceutical item.  Each of the persons determined in the instrument to be responsible persons has given the required notification to the Minister.

The PBAC is an independent expert body established by section 100A which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.  PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions.  Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.  When recommending the listing of a medicine on the PBS, the PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.


ATTACHMENT

Paragraph 1: provides that this instrument commences on 1 May 2010.

Paragraph 2: provides that Schedule 1 amends PB 16 of 2010.

Schedule 1: provides for the following amendments:

 

SCHEDULE 1

Additions

Listed Drug

Form

Brand

Responsible Person

Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids

Oral powder 400 g (EleCare LCP)

EleCare LCP

Abbott Australasia Pty Ltd

Carmellose with glycerin

Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, single dose units
0.4 mL, 30

Optive

Allergan Australia Pty Limited

Clopidogrel

Tablet 75 mg (as hydrogen sulfate)

APO-Clopidogrel

Apotex Pty Ltd

Clopidogrel

Tablet 75 mg (as hydrogen sulfate)

Chem mart Clopidogrel

Apotex Pty Ltd

Clopidogrel

Tablet 75 mg (as hydrogen sulfate)

Terry White Chemists Clopidogrel

Apotex Pty Ltd

Dasatinib

Tablet 100 mg

Sprycel

Bristol-Myers Squibb Australia Pty Ltd

Fludarabine

Powder for I.V. injection containing fludarabine phosphate 50 mg

Farine

Willow Pharmaceuticals Pty Ltd

Interferon Beta-1a

Solution for injection 132 micrograms in 1.5 mL multidose cartridge

Rebif 44

Merck Serono Australia Pty Ltd

Irinotecan

I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL

Tecan

Willow Pharmaceuticals Pty Ltd

Irinotecan

I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL

Tecan

Willow Pharmaceuticals Pty Ltd

Lacosamide

Tablet 50 mg

Vimpat

UCB Australia Proprietary Limited

Lacosamide

Tablet 100 mg

Vimpat

UCB Australia Proprietary Limited

Lacosamide

Tablets 100 mg, 14

Vimpat

UCB Australia Proprietary Limited

Lacosamide

Tablet 150 mg

Vimpat

UCB Australia Proprietary Limited

Lacosamide

Tablets 150 mg, 14

Vimpat

UCB Australia Proprietary Limited

Lacosamide

Tablet 200 mg

Vimpat

UCB Australia Proprietary Limited

Lansoprazole

Capsule 30 mg

APO-Lansoprazole

Apotex Pty Ltd

Lansoprazole

Capsule 30 mg

Lanzopran

Ranbaxy Australia Pty Limited

Levodopa with Carbidopa and Entacapone

Tablet 75 mg-18.75 mg-200 mg

Stalevo 75/18.75/200mg

Novartis Pharmaceuticals Australia Pty Limited

Levodopa with Carbidopa and Entacapone

Tablet 125 mg-31.25 mg-200 mg

Stalevo 125/31.25/200mg

Novartis Pharmaceuticals Australia Pty Limited

Metformin

Tablet containing metformin hydrochloride 850 mg

Metformin-GA

Genepharm Pty Ltd

Pantoprazole

Tablet (enteric coated)
20 mg (as sodium sesquihydrate)

Pantoprazole-GA

Genepharm Pty Ltd

Pantoprazole

Tablet (enteric coated)
40 mg (as sodium sesquihydrate)

Pantoprazole-GA

Genepharm Pty Ltd

Paroxetine

Tablet 20 mg (as mesilate)

Pharmacor Paroxo 20

Meditech Int. Pty Ltd

Perindopril

Tablet containing perindopril erbumine 2 mg

Perindopril-GA

Genepharm Pty Ltd

Perindopril

Tablet containing perindopril erbumine 4 mg

Perindopril-GA

Genepharm Pty Ltd

Perindopril

Tablet containing perindopril erbumine 8 mg

Perindopril-GA

Genepharm Pty Ltd

Pravastatin

Tablet containing pravastatin sodium 40 mg

Pravastatin Sandoz

Sandoz Pty Ltd

Simvastatin

Tablet 10 mg

Pharmacor Simvastatin 10

Meditech Int. Pty Ltd

Simvastatin

Tablet 20 mg

Pharmacor Simvastatin 20

Meditech Int. Pty Ltd

Simvastatin

Tablet 40 mg

Pharmacor Simvastatin 40

Meditech Int. Pty Ltd

Simvastatin

Tablet 80 mg

Pharmacor Simvastatin 80

Meditech Int. Pty Ltd

Terbinafine

Tablet 250 mg (as hydrochloride)

Terbix 250

Meditech Int. Pty Ltd

 

 

 

 

Deletions

 

Listed Drug

Form

Brand

Responsible Person

Diazepam

Tablet 5 mg

Diazepam-DP

Genepharm Pty Ltd

Fluoxetine

Capsule 20 mg (as hydrochloride)

Fluoxetine-DP

Genepharm Pty Ltd

Pravastatin

Tablet containing pravastatin sodium 40 mg

Liprachol

Sandoz Pty Ltd

 

Alteration of Forms and Brands

 

Listed Drug

Form

Brand

Responsible Person

Amino acid formula with vitamins and minerals without lysine and low in tryptophan

From: Oral powder 400 g (XLYS, LOW TRY Analog)

To: Oral powder 400 g (GA1 Anamix infant)

From: XLYS, LOW TRY Analog

To: GA1 Anamix infant

Nutricia Australia Pty Limited

Amino acid formula with vitamins and minerals without methionine

From: Oral powder 400 g (XMET Analog)

To: Oral powder 400 g (HCU Anamix infant)

From: XMET Analog

To: HCU Anamix infant

Nutricia Australia Pty Limited

Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine

From: Oral powder 400 g (XMTVI Analog)

To: Oral powder 400 g (MMA/PA Anamix infant)

From: XMTVI Analog

To: MMA/PA Anamix infant

Nutricia Australia Pty Limited

Amino acid formula with vitamins and minerals without phenylalanine and tyrosine

From: Oral powder 400 g (Xphen, Tyr Analog)

To: Oral powder 400 g (TYR Anamix infant)

From: Xphen, Tyr Analog

To: TYR Anamix infant

Nutricia Australia Pty Limited

Amino acid formula with vitamins and minerals without valine, leucine and isoleucine

From: Oral powder 400 g (MSUD Analog)

To: Oral powder 400 g (MSUD Anamix infant)

From: MSUD Analog

To: MSUD Anamix infant

Nutricia Australia Pty Limited

Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine

From: Oral powder 400 g (XP Analog LCP)

To: Oral powder 400 g (PKU Anamix infant)

From: XP Analog LCP

To: PKU Anamix infant

Nutricia Australia Pty Limited

 

Alteration of Brands

 

Listed Drug

Form

Brand

Responsible Person

Alprazolam

Tablet 250 micrograms

From: Zamhexal 0.25mg

To: Alprazolam Sandoz

Sandoz Pty Ltd

Ciprofloxacin

Tablet 750 mg (as hydrochloride)

From: Profloxin

To: Ciprofloxacin Sandoz

Sandoz Pty Ltd

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 25 mg

From: Diclohexal

To: Diclofenac Sandoz

Sandoz Pty Ltd

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 50 mg

From: Diclohexal

To: Diclofenac Sandoz

Sandoz Pty Ltd

 

Alteration of Responsible Person

 

Listed Drug

Form

Brand

Responsible Person

Imipramine

Tablet containing imipramine hydrochloride 10 mg

Tolerade 10

From:

Aspen Pharmacare Australia Pty Limited

To:

PMIP Pty Ltd (this Responsible Person is identified as a corporation by the company name and the ACN number)

Imipramine

Tablet containing imipramine hydrochloride 25 mg

Tolerade 25

From:

Aspen Pharmacare Australia Pty Limited

To:

PMIP Pty Ltd (this Responsible Person is identified as a corporation by the company name and the ACN number)

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.